Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Genmab said the first interim analysis of its first-line trial in PD-L1-positive recurrent or metastatic head and neck cancer showed statistically significant, clinically meaningful improvement in overall survival and objective response with a petosemtamab combination.
The EPCORE DLBCL-2 trial showed that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients.